These studies have highlighted the high prevalence of HαT among cMCADs patients, the associated elevation in baseline serum tryptase levels—which can influence both diagnosis and disease monitoring—and distinct clinical features, notably an increased risk of severe anaphylaxis. This evidence concerns the gene TMPRSS11D and anaphylaxis.